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ABSTRACT
Introduction: Telmisartan, an angiotensin receptor
blocker, has beneficial effects on insulin resistance and
cardiovascular health in non-HIV populations. This trial
will evaluate whether telmisartan can reduce insulin
resistance in HIV-positive individuals on combination
antiretroviral therapy.
Methods and analysis: This is a phase II,
multicentre, randomised, open-labelled, dose-ranging
trial of telmisartan in 336 HIV-positive individuals over
a period of 48 weeks. The trial will use an adaptive
design to inform the optimal dose of telmisartan.
Patients will be randomised initially 1:1:1:1 to receive
one of the three doses of telmisartan (20, 40 and
80 mg) or no intervention (control). An interim
analysis will be performed when half of the planned
maximum of 336 patients have been followed up for at
least 24 weeks. The second stage of the study will
depend on the results of interim analysis. The primary
outcome measure is a reduction in insulin resistance
(as measured by Homeostatic Model Assessment—
Insulin Resistance (HOMA-IR)) in telmisartan treated
arm(s) after 24 weeks of treatment in comparison with
the non-intervention arm. The secondary outcome
measures include changes in lipid profile; body fat
redistribution (as measured by MRI); plasma and
urinary levels of various biomarkers of cardiometabolic
and renal health at 12, 24 and 48 weeks. Serious
adverse events will be compared between different
telmisartan treated dose arm(s) and the control arm.
Ethics and dissemination: The study, this protocol
and related documents have been approved by the
National Research Ethics Service Committee North
West—Liverpool Central (Ref: 12/NW/0214). On
successful completion, study data will be shared with
academic collaborators. The findings from TAILoR will
be disseminated through peer-reviewed publications, at
scientific conferences, the media and through patient
and public involvement.
Trial registration numbers: 04196/0024/001-0001;
EUDRACT: 2012-000935-18; ISRCTN: 51069819.
BACKGROUND AND RATIONALE
Combination antiretroviral therapy (cART) is
the mainstay for treatment of HIV and has
dramatically improved the morbidity and
mortality associated with HIV, turning it into
a chronic disease. However, cART, together
Strengths and limitations of this study
▪ This clinical trial will evaluate whether telmisar-
tan can reduce insulin resistance in HIV-positive
individuals on combination antiretroviral therapy;
this may lead to the repositioning of telmisartan
to treat metabolic disease.
▪ The trial will use an adaptive design to inform
the optimal dose of telmisartan for reduction of
insulin resistance. This design also allows stop-
ping of the trial midway if none of the doses
show a statistically significant effect after the
interim analysis, thereby reducing the duration of
trial and related costs.
▪ The trial is assessing a surrogate marker (insulin
resistance) as an outcome measure in this trial.
Despite the fact that there is a good relationship
between insulin resistance and cardiovascular
health, this represents a limitation of the trial.
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with the virus itself, can result in various metabolic com-
plications, including metabolic syndrome, type 2 dia-
betes (T2DM) and an increased risk of cardiovascular
disease (CVD).1 These metabolic complications asso-
ciated with cART also occur with HIV lipodystrophy
(also known as the fat redistribution syndrome), a clus-
tering of morphological and metabolic abnormalities
comprising peripheral fat loss (lipoatrophy), visceral
lipid hypertrophy, insulin resistance and dyslipidaemia,2
which also increases the risk of CVD.3
The prevalence of metabolic syndrome is high in
cART treated HIV-infected patients (ranges from 11.2–
45.4% in different HIV populations);4 the HIV DAD
cohort (n=33 347) found the prevalence of metabolic
syndrome to increase from 19.4% to 41.6% over a 6-year
period with patients having metabolic syndrome showing
a fourfold increase in the incidence of T2DM and a
twofold to threefold increased risk of developing CVD.5
These results have been conﬁrmed by the Multicenter
AIDS Cohort Study (n=1278)6 and a more recent ana-
lysis of the DAD cohort.7 Cumulative exposure to cART
also results in an increased risk of myocardial infarction
with both protease inhibitors8 (PIs) and nucleoside
reverse transcriptase inhibitors9 (NRTIs), as well as in
intima-media thickness and an increase in the preva-
lence of carotid lesions.10
Insulin resistance, a key feature of HIV lipodystrophy
and metabolic syndrome, has been described as central
to cardiometabolic disease and is considered to be an
important link between features of metabolic syndrome,
obesity, dyslipidaemia, T2DM and CVD.11 In vitro
studies12 and single drug studies in healthy individuals13
and HIV-infected patients14 15 have shown that PIs and
NRTIs cause insulin resistance. The prevalence of
insulin resistance in cART-treated HIV-infected patients
ranges from 10 to 37%,14–16 indicating a signiﬁcant role
for cART in its development. Several mechanisms have
been suggested to be responsible for cART-induced
insulin resistance; these include cART-induced inhib-
ition of adipocyte differentiation,17 increased secretion
of adipokines such as interleukin 6 (IL-6) and tumour
necrosis factor α (TNF-α),18 and impairment of the
insulin signalling pathway.12
Clinical intervention to arrest or reverse cART-associated
insulin resistance has been suggested as a strategy to
reduce the incidence of T2DM and CVD in HIV-positive
patients. Insulin sensitisers such as thiazolidinediones and
metformin have been trialled but results from randomised
clinical trials in HIV patients have shown mixed
results.19 20 Moreover, the associated adverse effects may
limit their use in HIV-infected patients.21 22 Therefore,
there is a need for novel clinical interventions with proven
safety proﬁle that can reduce cART-induced insulin resist-
ance in HIV-infected individuals.
Some angiotensin receptor blockers (ARBs) have a
beneﬁcial effect on insulin resistance and T2DM, owing
to their action on the renin-angiotensin system and
partial agonist activity at PPARγ, an important regulator
of adipocyte function. Telmisartan shows maximal
potency on PPARγ when compared to other ARBs and
has been reported to reduce insulin resistance in several
in vitro,23 24 animal25 26 and clinical studies.27–30
Telmisartan also improves adiponectin levels, an import-
ant metabolic marker of insulin resistance and athero-
sclerotic disease, lipid control, and has favourable effects
on fasting serum insulin and high sensitivity C reactive
protein27 (high-sensitivity C reactive protein (hs-CRP); a
marker of CVD). Telmisartan has also been shown to
reduce visceral, but not subcutaneous, fat accumulation
in patients with metabolic syndrome.31 32 Importantly,
telmisartan already has a license for cardiovascular pro-
tection in a broad group of at-risk patients (ONTARGET
trial; 120 000 patient-years of follow-up).33
In contrast to the non-HIV population, the effect of
telmisartan on insulin resistance in cART-treated
HIV-positive patients has not been assessed. Using in
vitro adipocyte models, we (Pushpakom, unpublished)
and others34 have shown that telmisartan partially
reverses the antiadipogenic effects of antiretrovirals. Our
trial has therefore been designed to address this.
Furthermore, although the dose-response relationship of
telmisartan in hypertension is well known, whether this
would also be similar in reducing insulin resistance is
unclear. Our in vitro study in fact suggested that there
might be a non-monotone (bell shaped) relationship of
telmisartan on markers of adipocyte health. We have
therefore utilised an adaptive trial design during the
initial stage of the study to carefully assess the dose–
response relationship of telmisartan in vivo.
OBJECTIVES
The primary objective of the trial is to determine the
effect of telmisartan on insulin resistance in HIV-positive
individuals on cART using Homeostatic Model
Assessment—Insulin Resistance (HOMA-IR). HOMA-IR
is a measurable, validated surrogate marker of insulin
resistance.35
The secondary objectives include assessing the optimal
dose of telmisartan that can signiﬁcantly reduce insulin
resistance, evaluation of tolerability of telmisartan in
HIV patients and mechanistic evaluation of the meta-
bolic effects of telmisartan. The mechanistic evaluation
of telmisartan will explore longitudinal changes in
plasma markers that are important indicators of cardio-
metabolic health (adiponectin, IL-6, resistin, TNFα,
hs-CRP and lipids) at different time points; it will also
utilise MRI and 1H MR spectroscopy (MRS) to assess the
effect of telmisartan on total body fat and intrahepatic
and intramyocellular triglyceride content, respectively.
The MRI/MRS evaluation will be limited to a subset of
participants who are recruited locally.
Telmisartan is known to possess renoprotective
effects;36 37 in addition to the above objectives, the study
will also assess its effects on the kidney using urinary
markers of renal injury (conventional markers such as
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creatinine, urea, total protein and novel biomarkers
such as KIM-1, NGAL and RBP).
TRIAL DESIGN
This study is a phase II, multicentre, randomised, open-
labelled, dose-ranging trial of telmisartan in HIV-positive
individuals over a period of 48 weeks. The sample size
for the study is 336 (see Sample size calculation), but a
total of 370 patients will be recruited to participate in
this study to account for patient withdrawals (estimated
to be 10%).
The optimal dose of telmisartan that elicits the
desired response is not known; hence, an adaptive
design is utilised for this study. The ﬁrst stage of the
study will be dose-ranging where patients will be rando-
mised 1:1:1:1 to receive one of three doses of telmisartan
(20, 40 and 80 mg) or no intervention (control). An
interim analysis will be performed when half of the
planned maximum of 336 patients have been followed
up for at least 24 weeks. The second stage of the study
will depend on the results of interim analysis, which
could be one of the three outcomes listed below:
1. One or more active dose groups are substantially
more effective than control; this will lead to a stop-
ping of the study and the corresponding dose(s) will
be taken directly into phase III.
2. No dose shows sufﬁcient promise at the interim ana-
lysis; this will also lead to a stopping of the study.
3. At least one of the doses shows some improvement
over control at interim analysis; this will lead to a
second stage where that/these dose(s) will be fol-
lowed up along with the control for a further
24 weeks (total: 48 weeks). Additional patients will
also be recruited to these dose(s) and control. If at
the ﬁnal analysis a large enough reduction in
24 week HOMA-IR score is found, the corresponding
active dose will be recommended for phase III.
In the telmisartan 40 and 80 mg arms, dose titration
will be undertaken over 2−4 weeks in order to step up to
the allocated dose (as per the Summary of Product
Characteristics; SPC), or else the maximum tolerated
dose if the target is not achieved. All assessments will be
carried out at baseline and at weeks 12, 24 and 48 post-
treatment with telmisartan, as well as in the control arm.
For those who participate in the MRI/MRS substudy,
assessment will be at baseline and 24 weeks. The study
ﬂow diagram is given in ﬁgure 1.
The Clinical Trials Research Centre (CTRC),
University of Liverpool, is the coordinating centre for
this study (http://www.liv.ac.uk/translational-medicine/
research/ctrc/about/).
PATIENT RECRUITMENT
Identification of eligible patients
Patients who are eligible for inclusion into the trial will
be identiﬁed and recruited through HIV specialty
centres located in the UK that have agreed to participate
in the study. These HIV specialty centres are part of the
secondary care system and are mostly based in an urban
setting. Participants will be identiﬁed by the clinical team
at each centre via a search of the patient database(s)
either electronically or manually or a clinic list review to
ﬁnd potentially eligible patients. The inclusion and
exclusion criteria are detailed in box 1.
Consent procedure
At the routine clinic visit, eligible patients are informed
of the study by a member of the clinical team or
research staff. A Patient Information Sheet and instruc-
tions on how to proceed if they are interested in taking
part will be provided by the research nurse. All patients
will be provided with a full explanation of the trial and
given sufﬁcient time to consider their decision before
obtaining informed written consent. In consenting to
the trial, patients are consenting to trial treatment,
follow-up and data collection. Patients are free to with-
draw consent at any time without providing a reason.
Follow-up of these patients will be continued through
the trial research nurses and the lead investigator at
each centre unless the participant explicitly also with-
draws consent for follow-up.
Baseline assessments
Once informed consent has been obtained from the
patient, they will be booked in for a baseline assessment
visit within 30 days of giving consent. The patient will
be advised to arrive fasting when reporting for the base-
line assessment. The research team will conduct the
baseline assessments and complete the eligibility and
baseline case report form (CRF) during the baseline
assessment visit. The baseline assessments include fulﬁl-
ment of eligibility criteria; recording demographic
details; full medical and drug history; body weight and
vital signs; and waist/thigh circumference. A urine preg-
nancy test is offered for females of childbearing poten-
tial since telmisartan is not recommended during the
ﬁrst trimester of pregnancy and is contraindicated
during the second and third trimesters of pregnancy
due to its teratogenic potential. However, a refusal to
undertake a pregnancy test will not preclude trial entry.
Blood samples (for plasma, serum and DNA) and urine
will also be collected from each patient at the time of
baseline screening. Table 1 details the schedule of study
assessments conducted.
RANDOMISATION
Participants will be randomised to receive telmisartan
20, 40, 80 or control (no intervention) in a 1:1:1:1 ratio
once (A) eligibility criteria have been fulﬁlled; (B) fully
informed written consent has been obtained; and (C)
baseline assessments have been completed. Participants
will be randomised using a bespoke secure (24 h) web
based randomisation programme controlled centrally by
the CTRC, University of Liverpool. For each recruiting
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centre, randomisation will be stratiﬁed by ethnicity
(African-American and non-African-American) where
ethnicity is determined by self-categorisation using the
NHS ethnicity codes. Centres will be provided with
emergency back-up randomisation envelopes to be used
in the event of a system failure or when a system failure
cannot be resolved in a reasonable time frame. Patients
may only be randomised into the study by an authorised
member of staff at the study site as detailed on the dele-
gation log. Participants may only be randomised into the
study once.
TRIAL INTERVENTIONS
Telmisartan is an angiotensin receptor antagonist indi-
cated for clinical use as an antihypertensive agent. It is
also used to reduce cardiovascular events in patients
who are at risk. However, the current trial uses telmisar-
tan outside its licensed indications.
At the onset of the trial, telmisartan was under patent
(Boehringer Ingelheim GmBH; Micardis); however,
during the course of the trial, the patent expired and
several manufacturers started marketing generic
telmisartan, which was then also used in the trial, but
the trial will continue to use Micardis SPC as the refer-
ence SPC. Telmisartan used in this trial is sourced via
usual local NHS procurement arrangements.
Telmisartan tablets are available in 20, 40 or 80 mg
doses and therefore ﬁt in with the dose range to be
used in the trial prior to interim analysis. In most cases,
the participant is provided their required dose in one
tablet. Telmisartan tablets are for once-daily oral admin-
istration and should be taken with liquid, with or
without food. The CRFs will be used to record which
brand has been dispensed to the participant.
Telmisartan is stored as per the manufacturer’s SPC.
For each randomised patient, treatment is for a
maximum period of 48 weeks. The principal investigator
or delegated other will issue a prescription based on the
patient’s randomisation status and the trial treatment
can start immediately after randomisation. For the three
treatment arms, treatments will be dispensed at the
appropriate doses at baseline, at 12 weeks and then at
24 weeks, unless interruption or discontinuation is war-
ranted. Wherever titration of dose is required, the treat-
ment starts with 20 mg and is then titrated upwards over
Figure 1 Flow Diagram for TAILoR Trial. The trial will be conducted in two stages. Stage 1 of the study is dose-ranging and
patients will be randomised 1:1:1:1 to receive one of three doses of telmisartan or no intervention (control). An interim analysis
will be performed when half of the planned maximum of 336 patients have been followed up for at least 24 weeks. Stage II of the
study will depend on the results of interim analysis, which could be one of the three outcomes shown in the figure. All
assessments will be carried out at baseline and at weeks 12, 24 and 48 post-treatment with telmisartan, as well as in the control
arm. For those who participate in the MRI/MRS substudy, assessment will be at baseline and 24 weeks. TEL: Telmisartan.
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a period of 2 weeks (for a 40 mg dose) or 4 weeks (for
an 80 mg dose). At 48 weeks, administration of trial
treatments will be stopped and any unused medications
will be returned to pharmacy for disposal via their local
procedures. There is a 2 week attendance window on
either side of each of the follow-up visits and a 4 day
window on either side of the titration visits.
Since the results of the interim analysis decide the
design of stage II of the trial, those patients who are on a
dose that is not taken forward to stage II will be asked to
stop taking the medication completely. These patients
will continue to be monitored for any adverse events for a
period of 7 days (washout period for telmisartan) after
which they will no longer be part of the trial and will
return to routine care. For those who are on trial arms
whose dose(s) are taken forward to stage II, they will be
asked to continue on the same dose for a further
24 weeks. Since treatment is not stopped between stages I
and II, some participants may receive up to a maximum
of 48 weeks trial treatment before the results of the
interim analysis are known. For patients recruited after
the results of interim analysis are known, they will be ran-
domised equally to the non-intervention (control) arm
and the remaining telmisartan dose arm(s).
Dose modiﬁcations will be allowed in those who are
randomised to a particular dose arm but do not tolerate
that dose. The patient will be allowed to continue on
the nearest dose tolerated. Those who show adverse
effects as a result of the trial intervention or due to the
HIV therapy may be withdrawn from the trial treatment.
The decision to interrupt or discontinue trial therapy is
at the discretion of the treating physician using their
informed clinical opinion. Any changes will be docu-
mented in the CRF along with the justiﬁcation for those
changes. Patients who withdraw from study treatment
will be asked to allow continuation of scheduled evalua-
tions, complete an end-of-study evaluation if appropriate
and be given appropriate care under medical supervi-
sion until the symptoms of any adverse event resolve or
the patient’s condition becomes stable. Follow-up of
these patients will be continued through the trial
research nurses and the lead investigator at each centre
unless the participant explicitly also withdraws consent
for follow-up. Data up to the time of withdrawal will be
included in the analyses unless the patient explicitly
states that this is not their wish.
PATIENT FOLLOW-UP
Apart from the dose-titration visits for participants in the
40 and 80 mg arms, follow-up visits will be designed to
ﬁt with routine hospital visits where possible. The study
will also allow a 2 week window on either side of the
scheduled follow-up visit date to ensure ﬂexibility.
Individual patients will be sent reminders about
follow-up visits by the research nurses provided they
have agreed to receive them. If any of the trial patients
are lost to follow-up, contact will be attempted through
the research nurse and lead investigator at each centre.
Wherever possible, information on the reason for loss to
follow-up will be recorded.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Adult (age 18 or above) HIV-positive individuals receiving
antiretroviral therapy for at least 6 months. The antiretroviral
therapy may contain:
▸ A boosted protease inhibitor (LPV/r, ATV/r, DRV/r,
FAPV/r, SQV/r)
▸ and/or efavirenz, rilpivirine or etravirine
The backbone can be based on N(t)RTI, raltegravir or maraviroc.
Patients on protease inhibitor monotherapy will be included if
they meet other criteria. Patients on nevirapine or dolutegravir
regimens, without concomitant boosted PIs, should not be
included. Additionally, patients on elvitegravir, which is adminis-
tered in combination with cobicistat (as Stribild), should not be
recruited.
2. Ability to give informed consent
3. Willingness to comply with all study requirements
Exclusion criteria
1. Pre-existing diagnosis of type 1 or 2 diabetes (Fasting
glucose >7.2 mmol/L or HbA1c≥6.5% [48 mmol/mol] or
abnormal OGTT or random plasma glucose≥11 mmol/L)
2. Patients known to have consistently low blood pressure (pre-
existing hypotension; A reading below a threshold of 100/
60 mm Hg on three separate occasions)
3. Patients with renal disease (eGFR<60 in the 6 months pre-
ceding randomisation)
4. Patients with known untreated renal artery stenosis
5. Patients with cholestasis, biliary obstructive disorders or
severe hepatic impairment.
6. Patients with evidence of an active, chronic hepatitis C
infection
7. Patients who are on unboosted ATV
8. Patients who are on/ have been on hormone therapy, ana-
bolics and insulin sensitisers within 6 months preceding ran-
domisation. Patients on hormonal contraception are eligible.
9. Patients who are already on/ have been on other ARBs, ACE
inhibitors or direct renin inhibitors within 4 weeks preceding
randomisation.
10. Those with suspected poor compliance
11. Pregnant or lactating women
12. Women of childbearing age unless using reliable contracep-
tion, for example, coil, barrier method, hormonal contracep-
tive that does not interact with their antiretroviral therapy
13. Co-enrolment in other drug trials
14. Patients who have participated in a trial of an IMP likely to
influence insulin sensitivity, plasma insulin, glucose levels or
plasma lipid levels within 6 months preceding
randomisation.
15. For the subcohort of patients undergoing MRI/MRS, normal
MR exclusion criteria will apply (See Body fat distribution
substudy).
ARB, angiotensin receptor blockers; ATV, atazanavir; DRV, daruna-
vir; eGFR, estimated glomerular filtration rate; FAPV, fosamprena-
vir; HbA1c, glycated haemoglobin; IMP, investigational medicinal
product; LPV/r, lopinavir/ritonavir; N(t)RTI, nucleoside (nucleo-
tide) reverse transcriptase inhibitors; OGTT, oral glucose tolerance
test; PI, protease inhibitor; SQV, saquinavir.
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Table 1 Schedule of study procedures
T+2 week T+4 weeks
Time
Pre T0
At each
recruitment
site
T0
Randomisation/
baseline*
Dose titration—
40/80 mg arms
(dose given
40 mg)
Dose titration
for 80 mg arm
(dose given
80 mg)
T+12
weeks
Follow-up
T+24
weeks
Follow-up
T+48
weeks
End of
treatment
Premature
withdrawal
of consent
Database search to identify potential
participants or clinic list review
Х
Information sheet provided to patient X
Signed informed consent Х
Assessment of eligibility criteria by a
medically qualified person
Х
Review of medical history (including
collection of most recent blood test results
for urea and electrolytes, eGFR, liver
function, diabetes screening, etc
Х† X Х
Review of concomitant medications Х Х Х Х Х Х Х
Urine pregnancy test Х X X
Randomisation Х
Study intervention Х Х Х Х Х
Compliance with study intervention—
patient diaries and pill counting
X X Х Х Х
Physical examination—complete Х
Physical examination—symptom-directed Х Х Х Х X Х
Height Х
Weight Х Х Х Х Х
Waist/thigh circumference Х Х Х Х Х
Heart rate, blood pressure Х Х Х Х Х Х Х
Collection of 3 fasting blood samples for
bioanalysis
Х Х Х Х Х
Collection of urine sample X X X X X
Assessment of adverse events Х Х Х Х Х Х
Consent for substudy X
MRI/MRS scan for substudy X X
(X)—As indicated/appropriate.
*Baseline assessment and randomisation visit should be within 30 days of the patient giving consent.
†Liver function and diabetes screening result only to be collected at baseline.
eGFR, estimated glomerular filtration rate; MRS, MR spectroscopy.
6
Pushpakom
SP,etal.BM
J
Open
2015;5:e009566.doi:10.1136/bm
jopen-2015-009566
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 O
ctober 19, 2015 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
OUTCOMES AND ASSESSMENTS
Efﬁcacy of trial treatments will be assessed throughout
the period of the study. The primary outcome measure
is a reduction in insulin resistance (as measured by
HOMA-IR) in telmisartan treated arm(s) after 24 weeks
of treatment in comparison with the non-intervention
arm. Fasting plasma and serum samples will be collected
from each participant at baseline and at follow-up visits
(weeks 12, 24 and 48) and stored under appropriate
conditions locally. Biochemical analyses will be carried
out centrally in an accredited clinical laboratory. Fasting
plasma glucose will be measured by standard clinical
methods and serum insulin will be measured by an elec-
trochemiluminescence immunoassay using a Cobas C
Analyser (Roche Diagnostics, Switzerland). HOMA-IR
will be calculated using the equation: (fasting serum
insulin (mU/L)×fasting plasma glucose (mmol/L))/
22.5. The secondary outcome measures are detailed in
box 2. Serum and urine biomarker analyses and DNA
extraction will be performed centrally using Human
Multiplex ELISA (Millipore) on a BioPlex 200 System
(BioRad) and Chemagic Magnetic Separation Module I
(MSM I), respectively.
Assessment of compliance with study treatment/s
All participants on intervention arms are given a treat-
ment diary to record their daily treatment compliance.
Compliance with the study treatment will be ascertained
on the basis of what is recorded in the treatment diary
and by recording the number of pills remaining in the
packs.
Body fat redistribution substudy
A substudy will be undertaken only for patients recruited
from the North West of UK to assess whether telmisartan
results in any changes in the total body adipose content
and intrahepatic and intramyocellular lipid content. This
will be assessed at baseline and at 24 weeks by MRI and
1H MRS in an on-site MRI research facility. Patients
recruited will be given a separate patient information
sheet and consent form containing information on the
substudy and requirements for MRI/MRS. Participants
will be allowed to withdraw from the substudy anytime
but remain in the main study. Only patients who consent
to take part in the main study and satisfy the normal MR
exclusion criteria (normal MR exclusion criteria include
patients using pacemakers, cochlear implants, piercings,
metal in the head or elsewhere in the body, and those
who suffer from claustrophobia) will be included in the
substudy. MRI of the total body adipose content will be
undertaken on a Siemens 1.5 T Symphony scanner
(Siemens, Erlangen Germany) using well-established
methods.38 MRI will be analysed to obtain volume esti-
mates of total body subcutaneous, total internal, subcuta-
neous abdominal and intra-abdominal adipose tissue. In
the same subcohort of patients, liver and skeletal muscle
1H MR spectra will be acquired using the Siemens body
coil and Siemens CP extremity coil, respectively, using
established methods.39 Analysis of all imaging data will be
conducted centrally.
SAMPLE SIZE CALCULATION
The primary response from each patient is the differ-
ence between the baseline HOMA-IR score and their
HOMA-IR score at 24 weeks. The design has been con-
structed under the assumption that for all patients this
response is normally distributed with a common SD, σ.
The sample size calculation is based on a one-sided
type I error of 5% and a power of 90%. If there is no dif-
ference between the mean response on any treatment
and that on control, then a probability of 0.05 is set for
the risk of erroneously ending the study with a recom-
mendation that any treatment be tested further. For the
power, we adopt a generalisation of this power require-
ment to multiple active treatments due to Dunnett.40
Effect sizes are speciﬁed as the percentage chance of a
patient on active treatment achieving a greater reduction
in HOMA-IR score than a patient on control as this spe-
ciﬁcation does not require knowledge of the common
SD, σ. The requirement is that, if a patient on the best
active dose has a 65% chance of a better response than
a patient on control, while patients on the other two
active treatments have a 55% chance of showing a better
response than a patient on control, then the best active
dose should be recommended for further testing with
probability 1−β=0.90. A 55% chance of achieving a
better response on active dose relative to control corre-
sponds to a reduction in mean HOMA-IR score of about
a sixth of an SD (0.178σ), while the clinically relevant
effect of 65% corresponds to a reduction of about half
an SD (0.545σ). The critical values for recommending
that a treatment is taken to further testing at the interim
Box 2 Secondary outcome measures
1. Change in lipid profile (total cholesterol, triglycerides, LDL-c
and HDL-c) at weeks 12, 24 and 48 between telmisartan
treated arm(s) and the control arm.
2. Change in body fat redistribution as measured by MRI/MRS at
24 weeks between telmisartan treated arm(s) and control arm
(See substudy).
3. Change in plasma concentrations of biomarkers (adiponectin,
lipin1, IL-6, TNF-α, resistin and hs-CRP) at 12, 24 and
48 weeks between telmisartan treated arm(s) and control arm.
4. Change in insulin resistance, measured longitudinally at weeks
12 and 48, in telmisartan treated arm(s) in comparison with
the control arm.
5. Change in urinary biomarker levels at 12, 24 and 48 weeks
between telmisartan treated arm(s) and the control arm.
6. Difference in expected and unexpected serious adverse events
between different telmisartan treated dose arm(s) and the
control arm over the study follow-up.
HDL-c, high density lipoprotein-cholesterol; hs-CRP, high sensi-
tive, C reactive protein; IL-6, interleukin-6; LDL-c, low density
lipoprotein-cholesterol; TNF-α, tumour necrosis factor-α.
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and ﬁnal analyses (2.782 and 2.086) have been chosen
to guarantee these properties using a method described
by Magirr et al,41 generalising the approach of
Whitehead and Jaki.42
The maximum sample size of this study is 336 evalu-
able patients, although the use of the interim analysis
may change the required sample size. The study will
recruit additional patients to account for an anticipated
10% dropout rate.
Interim monitoring and analyses
An interim analysis will take place once the primary end
point is available for at least 42 patients on each arm (ie,
half of the planned maximum of 336 patients). The
sample SD pooled across all four arms is used to con-
struct test statistics expressing the advantage of each of
the three active treatments over control. The analysis will
be proceeding as follows:
1. If the largest test statistic exceeds 2.782, the study will
be stopped and the corresponding dose will be
recommended for further testing.
2. If any active dose shows no improvement over control
(ie, has a negative test statistic), that active dose will
be dropped.
3. If no active dose shows an improvement over control,
the study will be stopped and no signiﬁcant improve-
ment over control will be claimed.
4. If some improvement over control is detected for at
least one dose (ie, at least one test statistic is between 0
and 2.782), the study will progress to the second stage.
At the interim analysis, doses may be dropped from
the trial, or the trial may be stopped altogether.
Consequently, the required sample size when the deci-
sion is reached could be smaller than the maximum
stated number of 336 patients. The values 168 (if the
study is stopped following interim analysis), 252 (if one
active dose arm is promoted to the second stage), 294
(if two active dose arms are promoted to the second
stage) and 336 (if all three active dose arms are pro-
moted to the second stage) are possible. The reduced
sample sizes refer to the numbers of patients with
24 week HOMA-IR scores which are included in the ana-
lysis. Evaluation of the patient withdrawal rate will be
carried out and the sample size will be adjusted accord-
ingly. There will be additional patients who have been
recruited during the 24 weeks prior to extracting the
data for interim analysis and their number will depend
on the recruitment rate achieved. A decision to discon-
tinue recruitment, in all patients or in selected sub-
groups, will be made on the basis of results from the
interim analysis by the Independent Data and Safety
Monitoring Committee (IDSMC).
STATISTICAL ANALYSIS
Primary outcome analysis
Three different doses of the intervention will be evalu-
ated against the control in stage 1 of the study and an
interim analysis will take place that will allow ineffective
doses to be eliminated quickly while a dose showing a
positive effect can be taken forward. An ANCOVA model
will be ﬁtted for a 24 week HOMA-IR score adjusting for
the stratiﬁcation factor (African-American and non-
African-American), and the corresponding t—values will
be used to construct test statistics expressing the advan-
tage of each of the active treatments over control. The
largest of these test statistics will be compared to the
interim critical value (2.782) and proceed as discussed
above at the interim analysis. At the ﬁnal analysis, if the
largest comparative test statistic exceeds the ﬁnal critical
value (2.086), then this dose would be recommended
for further study. Adjustments can be made to allow for
any discrepancies between target and actual sample sizes
while still preserving the one-sided type I error rate at
0.05.
Secondary outcome analysis
Linear mixed effect models will be used to analyse sec-
ondary and mechanistic outcomes. The evaluation of
beneﬁcial and adverse biomarkers in relation to insulin
resistance will be examined using the joint modelling
approach43 44 accounting for informative loss to
follow-up or censoring. Structural equation models45 will
be used to assess the inter-relationship between multiple
biomarkers over effect of treatment while accounting for
time-varying confounders. Mechanistic outcomes such as
change in body fat, liver and muscle fat distribution will
be analysed using a multiple linear regression model.
Differences will be considered signiﬁcant at p<0.05.
Differences between the groups will be estimated with
95% CIs.
SAFETY REPORTING
The CTRC will be notiﬁed of all serious adverse reac-
tions (SAR), serious adverse events (SAE) and suspected
unexpected serious adverse reactions (SUSARs) within
24 h of the local site becoming aware of the event. The
CTRC will notify the MHRA and main Research Ethics
Committee (REC) of all SUSARs occurring during the
study on behalf of the chief investigator according to the
following timelines: fatal and life-threatening within
7 days of notiﬁcation and non-life threatening within
15 days. It will also submit an annual report of all SAEs
to the sponsor, MHRA and the main REC and provide
the IDSMC with listings of all SAEs on an ongoing basis.
The study may be prematurely discontinued on the basis
of new safety information, or for other reasons given by
the IDSMC and/or Trial Steering Committee (TSC),
sponsor or REC concerned. All investigators will be
informed of all SUSARs occurring throughout the study.
The assignment of the severity/grading of adverse
events will be made by the investigator responsible for
the care of the participant using the Division of AIDS
Table for Grading the Severity of Adult and Paediatric
Adverse Events V.1.0 (2009) deﬁnitions.46 The CTRC
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will monitor SAE and ADR reporting rates across sites
during the course of the trial and if any inconsistencies
are noted, they will be investigated and additional train-
ing provided.
Reporting of pregnancy
Female study participants of childbearing potential will
be offered a pregnancy test as part of the trial screening
process and at weeks 12 and 24. Any pregnancy which
occurs during the study will be reported as an SAE to
the CTRC within 24 h of the site becoming aware of its
occurrence and the participant will be instructed imme-
diately to stop taking study drugs. All pregnancies that
occur during treatment need to be followed up until
after the outcome. The investigator will discuss the risks
of continuing with the pregnancy and the possible effect
to the fetus with the participant.
ETHICAL CONSIDERATIONS
The conduct of this study will be in accordance with the
Declaration of Helsinki, 1964 and later revisions.
The main ethical issue is the potential allocation of
participants to less effective treatment arms. In stage 1
of the trial, a quarter of the patients will be allocated to
the non-intervention control arm; it is also likely that
some of the intervention arms could be found to be less
effective during the interim analysis and hence be
dropped. However, these comparator arms are necessary
for the identiﬁcation of a positive drug effect in the
treatment arm(s) and its optimal dose. This does not
have any impact on the control of HIV infection since
the intended use of telmisartan in this patient popula-
tion is only as an adjuvant drug and not as the primary
drug to treat HIV infection.
Telmisartan is an antihypertensive drug, and thus
there is a possibility that some of the participants rando-
mised to the higher doses may experience hypotension.
The eligibility criteria aim to exclude those who consist-
ently show hypotension; moreover, the prevalence of
telmisartan-induced hypotension in normotensive indivi-
duals has been found to be rare in previous studies.47 48
However, the trial will take adequate precautions such as
routine blood pressure monitoring to address this issue.
There will be a minor increase in the pill burden to the
participants of this trial; however, this is not a major
issue since the intervention is available as a single tablet
that needs to be taken only once daily.
Other ethical issues include contraception for all
women of childbearing age during the course of the
trial and additional clinic visits required for baseline
assessments and dose titration (limited to only 40 and
80 mg arms). For a subset of patients recruited to under-
take the substudy, it may involve additional patient time
to undertake MRI/MRS scans. In the event that the
study is discontinued, participants will be treated accord-
ing to standard clinical care.
Ethical and regulatory approvals
The study, this protocol and related documents have
been approved by the National Research Ethics Service
Committee North West—Liverpool Central (Ref: 12/
NW/0214).
This study falls within the remit of the EU Directive
2001/20/EC, transposed into UK law as the UK
Statutory Instrument 2004 No 1031: Medicines for
Human Use (Clinical Trials) Regulations 2004 as
amended. This trial has been registered with the
Medicines and Healthcare Products Regulatory Agency
(MHRA) and granted a Clinical Trial Authorisation
(04196/0024/001-0001). The EUDRACT number is
2012-000935-18.
DATA COLLECTION AND TRIAL MONITORING
Data collection
Data management procedures for the trial will be devel-
oped and overseen by the CTRC, University of
Liverpool. The CTRC will provide training, essential
documentation and user support to the study centres,
and monitoring, if triggered by an incident or where
appropriate. All primary data will be entered into the
study CRF for this study. Each participant will be
assigned a unique screening number at the start of the
assessment, which will be recorded on the consent form
and the baseline assessment CRF and on all other docu-
ments used to record participant data. All original CRFs
will be returned to the CTRC. For the participant treat-
ment diaries, the participant initials and randomisation
number will be clearly labelled on all documents. The
laboratory read-outs will be obtained for blood, urine
samples and for the body fat distribution substudy from
automated equipment. These will be uploaded securely
to the central trial database.
Trial monitoring
Trial monitoring procedures for this study are based on
a risk assessment conducted by the CTRC, University of
Liverpool. Guidance issued by the MRC, Department of
Health and the MHRA on risk-adapted approaches to
the management of CTIMPs proposes a three-level cat-
egorisation for the potential risk associated with an
IMP.49 In this study, telmisartan is used outside the man-
ufacturer’s indication; therefore, the IMP here is cate-
gorised as Type B: ‘somewhat higher than that of standard
medical care’. This level of risk will inform the risk assess-
ment, regulatory requirements, nature and extent of the
monitoring, and the management processes used in the
trial.
Central monitoring
Data stored at the CTRC will be checked for missing or
unusual values and for consistency within participants
over time. Any suspect data will be returned to the site
in the form of data queries and sites are expected to
respond to these queries with an explanation/resolution
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to the discrepancies. There are a number of monitoring
features in place at the CTRC to ensure reliability and
validity of the trial data.
Clinical site monitoring
The CTRC personnel may need direct access to primary
data such as patient records and laboratory reports; since
this affects the patient’s conﬁdentiality, this fact is
included on the patient information sheet. Individual
participant medical information obtained as a result of
this study is considered conﬁdential and disclosure to
third parties is prohibited. Medical information may be
given to the participant’s medical team and all appropri-
ate medical personnel responsible for the participant’s
welfare. The only identiﬁable data transferred is the
consent form and this is disclosed in the patient informa-
tion sheet and consent form. The CTRC will preserve the
conﬁdentiality of participants taking part in the study and
The University of Liverpool is registered as a Data
Controller with the Information Commissioners Ofﬁce.
Trial management and oversight
Trial Management Group
The Trial Management Group (TMG) will be respon-
sible for the day-to-day running and management of the
trial and will meet, as a minimum, approximately 10
times a year. The TMG will comprise the Chief
Investigator, other lead investigators (clinical and non-
clinical) and members of the trial coordinating centre
(CTRC).
Trial Steering Committee
The TSC will meet at least once annually and will
provide overall supervision for the trial and provide
advice through its independent Chairperson. The ultim-
ate decision for the continuation of the trial lies with
the TSC. The TSC will consist of an independent chair-
person (with clinical expertise in HIV), two independ-
ent statisticians with expertise in adaptive trial design
and medical statistics, a user representative, the investiga-
tors, representatives of the research networks, sponsors
and principal investigators.
Independent Data and Safety Monitoring Committee
The IDSMC will meet at least once annually and will be
responsible for reviewing and assessing recruitment,
interim monitoring of safety and effectiveness, trial
conduct and external data. It will provide a recommen-
dation to the TSC concerning the continuation of the
study. The IDSMC will consist of an independent chair-
person (with clinical expertise in HIV) and two inde-
pendent members: one who is an expert in the ﬁeld of
HIV lipodystrophy, and one who is an expert in medical
statistics and adaptive trial design. Terms of reference
for the TMG and TSC and Charter for the IDSMC are
available on request from the CTRC, University of
Liverpool.
NOTIFICATION OF AMENDMENTS
Any amendments made to the study including protocol
amendments will be communicated to the appropriate
agencies for approval prior to implementation. All sub-
stantial amendments made will be reviewed by the
sponsor prior to submission to the REC and the MHRA
for their approval; substantial amendments will also be
notiﬁed to all participating research sites. All substantial
and non-substantial amendments as well as respective
regulatory approvals will be provided electronically via
the Integrated Research Application System (IRAS) to
the Clinical Research Network North West Coast who
will notify the Research and Development Department
at individual participating sites for local approval and
implementation.
TIME FRAME AND TRIAL STATUS
TAILoR is currently recruiting from 19 specialist HIV
centres throughout the UK. The study has so far
recruited 293 patients and has been given a no-cost
extension to continue recruitment till the end of July
2015. Each participant is followed up for a total of
48 months. The total study period is 56 months.
DISCUSSION
Metabolic disease and insulin resistance continue to be
a major problem in HIV-infected individuals; a recent
longitudinal study observed an overall insulin resistance
prevalence of 21% (using a HOMA-IR cut-off >3.8) in
HIV patients.50 Given that HIV is now considered a
chronic disease with an ageing population51 and the fact
that ageing further increases the susceptibility to
age-related comorbidities such as metabolic and CVD,
the magnitude of this problem is likely to become even
greater. This is exempliﬁed by the fact that the preva-
lence of insulin resistance in HIV patients increases with
age, ranging from 5% in patients <30 years to 30% in
patients over 60 years of age.50 Therefore, there is a
pressing need to develop or identify newer therapies to
combat metabolic disease in this group of individuals;
this trial will potentially address this need and may lead
to the repositioning of telmisartan to treat metabolic
disease.
Since the start of this trial, two smaller studies have
already reported beneﬁcial metabolic effects of telmisar-
tan in cART-treated HIV patients. While one study
observed a reduction in HOMA-IR with 80 mg telmisar-
tan,52 the other did not ﬁnd a reduction in HOMA-IR
but observed a loss of total and subcutaneous fat with a
40 mg dose.53 This clearly underlines the need for a
well-powered trial to conﬁrm the efﬁcacy of telmisartan
for reducing insulin resistance and this is met by the
current study. The trial also utilises a novel adaptive
design which will enable identiﬁcation of the optimal
dose of telmisartan, if ultimately it is found to elicit a
statistically signiﬁcant beneﬁcial effect on insulin resist-
ance. The adaptive design also allows stopping of the
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trial midway if none of the doses show a statistically sig-
niﬁcant effect after the interim analysis; this will reduce
the duration of the trial and result in cost saving.
Of course, we are assessing a surrogate marker
(insulin resistance) as an outcome measure in this trial.
Despite the fact that there is a good relationship
between insulin resistance and cardiovascular
health,54 55 this represent a limitation of the trial.
However, this is a phase IIb trial, and thus a surrogate
marker as a primary outcome measure is justiﬁed,
because a trial to show a reduction in cardiovascular end
points will necessarily need to be large and would be
reserved for a follow-on phase III design.
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